Attorneys:
Ropes & Gray advised Genzyme Corporation on the $2.9 billion deal with Bayer Schering Pharma AG that received a “Deal of Distinction” award from the Licensing Executives Society. The 2009 deal bolstered Genzyme’s oncology portfolio by giving the company rights to marketed cancer drugs and control of a program in multiple sclerosis.
The “Deal of Distinction” award recognizes the most distinctive deal in the life sciences sector in 2009. The Licensing Executives Society is a professional society with nearly 5,000 members engaged in the development, use, transfer, marketing, and management of intellectual property.
The cross-practice Ropes & Gray deal team was led by Boston-based corporate partners Chris Comeau (Securities & Public Companies), David McIntosh (IP Transactions), Walter McCabe (Real Estate) and Paul Kinsella (Securities & Public Companies).
The “Deal of Distinction” award recognizes the most distinctive deal in the life sciences sector in 2009. The Licensing Executives Society is a professional society with nearly 5,000 members engaged in the development, use, transfer, marketing, and management of intellectual property.
The cross-practice Ropes & Gray deal team was led by Boston-based corporate partners Chris Comeau (Securities & Public Companies), David McIntosh (IP Transactions), Walter McCabe (Real Estate) and Paul Kinsella (Securities & Public Companies).
Stay Up To Date with Ropes & Gray
Subscribe to Our Podcast
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Follow Us on Social
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
Join Our Mailing List
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.